Estrella Immunopharma Inc., a clinical stage biopharmaceutical company, has announced a new partnership with the Baylor Research Institute, operating as Baylor Scott & White Research Institute in Dallas, Texas. This collaboration marks a significant development in Estrella's ongoing STARLIGHT-1 Phase I/II clinical trial, which is focused on evaluating EB103, a CD19-Redirected ARTEMIS® T-cell therapy, for patients with relapsed or refractory B-cell non-Hodgkin's lymphoma (NHL). The partnership aims to expand the clinical footprint, accelerating the development of EB103 and enhancing patient access to this promising therapy. The Baylor Research Institute will serve as a new clinical site, now open for patient enrollment, furthering Estrella's mission to deliver safer and more effective treatments for NHL patients.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。